O'Riordan TG[au] - Search Results

Year	Number of Results
1990	1
1991	2
1992	3
1993	2
1994	3
1995	1
1996	4
1997	2
1998	2
1999	4
2000	1
2001	1
2002	2
2003	2
2004	2
2005	2
2006	1
2007	1
2013	4
2014	9
2015	6
2016	2
2017	3
2018	2
2019	1
2020	1
2023	0

1

Wanner A, Salathé M, O'Riordan TG. Wanner A, et al. Among authors: o riordan tg. Am J Respir Crit Care Med. 1996 Dec;154(6 Pt 1):1868-902. doi: 10.1164/ajrccm.154.6.8970383. Am J Respir Crit Care Med. 1996. PMID: 8970383 Review. No abstract available.

2

Formulations and nebulizer performance.

O'Riordan TG. O'Riordan TG. Respir Care. 2002 Nov;47(11):1305-12; discussion 1312-3. Respir Care. 2002. PMID: 12425745 Review.

3

Treatment of mucociliary dysfunction.

Salathe M, O'Riordan TG, Wanner A. Salathe M, et al. Among authors: o riordan tg. Chest. 1996 Oct;110(4):1048-57. doi: 10.1378/chest.110.4.1048. Chest. 1996. PMID: 8874267 Free article. Review. No abstract available.

4

Aerosol delivery devices and obstructive airway disease.

O'Riordan TG. O'Riordan TG. Expert Rev Med Devices. 2005 Mar;2(2):197-203. doi: 10.1586/17434440.2.2.197. Expert Rev Med Devices. 2005. PMID: 16293056 Review.

5

Respiratory medical societies and the threat of bioterrorism.

O'Riordan TG, Smaldone GC. O'Riordan TG, et al. Thorax. 2004 Mar;59(3):265-7. doi: 10.1136/thorax.2003.015321. Thorax. 2004. PMID: 14985568 Free PMC article. Review.

6

A preliminary quality of life questionnaire-bronchiectasis: a patient-reported outcome measure for bronchiectasis.

Quittner AL, Marciel KK, Salathe MA, O'Donnell AE, Gotfried MH, Ilowite JS, Metersky ML, Flume PA, Lewis SA, McKevitt M, Montgomery AB, O'Riordan TG, Barker AF. Quittner AL, et al. Among authors: o riordan tg. Chest. 2014 Aug;146(2):437-448. doi: 10.1378/chest.13-1891. Chest. 2014. PMID: 24626872 Review.

7

Optimizing delivery of inhaled corticosteroids: matching drugs with devices.

O'Riordan TG. O'Riordan TG. J Aerosol Med. 2002 Fall;15(3):245-50. doi: 10.1089/089426802760292582. J Aerosol Med. 2002. PMID: 12396412 Review.

8

Risk factors for disease progression in idiopathic pulmonary fibrosis.

Raghu G, Ley B, Brown KK, Cottin V, Gibson KF, Kaner RJ, Lederer DJ, Noble PW, Song JW, Wells AU, Whelan TP, Lynch DA, Humphries SM, Moreau E, Goodman K, Patterson SD, Smith V, Gong Q, Sundy JS, O'Riordan TG, Martinez FJ. Raghu G, et al. Among authors: o riordan tg. Thorax. 2020 Jan;75(1):78-80. doi: 10.1136/thoraxjnl-2019-213620. Epub 2019 Oct 14. Thorax. 2020. PMID: 31611341

9

Potential role of inhibitors of neutrophil elastase in treating diseases of the airway.

Chughtai B, O'Riordan TG. Chughtai B, et al. Among authors: o riordan tg. J Aerosol Med. 2004 Winter;17(4):289-98. doi: 10.1089/jam.2004.17.289. J Aerosol Med. 2004. PMID: 15684729 Review.

10

Development of novel agents for idiopathic pulmonary fibrosis: progress in target selection and clinical trial design.

O'Riordan TG, Smith V, Raghu G. O'Riordan TG, et al. Chest. 2015 Oct;148(4):1083-1092. doi: 10.1378/chest.14-3218. Chest. 2015. PMID: 26020856 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results